Comparative Pharmacology
Head-to-head clinical analysis: PIASKY versus TASCENSO ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIASKY versus TASCENSO ODT.
PIASKY vs TASCENSO ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PIASKY is a small molecule inhibitor of Bruton's tyrosine kinase (BTK), which irreversibly binds to the active site of BTK, blocking B-cell receptor signaling and inhibiting B-cell proliferation and survival.
Fingolimod is a sphingosine 1-phosphate receptor modulator. It binds to S1P receptors on lymphocytes, inducing internalization and degradation of the receptor, thereby preventing egress of lymphocytes from lymph nodes, reducing peripheral lymphocyte count and immune-mediated demyelination in the central nervous system.
10 mg orally twice daily
14 mg orally once daily, with or without food. Swallow whole; do not crush, chew, or dissolve.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in healthy adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-60 mL/min) and up to 24 hours in severe impairment (CrCl <30 mL/min).
Terminal elimination half-life is 48-56 hours, supporting once-daily dosing.
Primarily renal excretion as unchanged drug (approx. 80-90%) with minor biliary/fecal elimination (5-10%).
Renal: ~80% unchanged; biliary/fecal: ~20% as metabolites.
Category C
Category C
Sphingosine 1-Phosphate Receptor Modulator
Sphingosine 1-Phosphate Receptor Modulator